Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE
Entity
UAM. Departamento de MedicinaPublisher
Oxford University PressDate
2021-09-16Citation
10.1093/rheumatology/keab628
Rheumatology 61.5 (2022): 1867-1876
ISSN
1462-0324 (print); 1462-0332 (online)DOI
10.1093/rheumatology/keab628Editor's Version
https://doi.org/10.1093/rheumatology/keab628Subjects
biological DMARDs; clinical outcome; GLOESS; joints; OMERACT; Power Doppler ultrasound; PsA; responsiveness; secukinumab; synovitis; MedicinaRights
© The Author(s) 2021Abstract
Objectives: To investigate the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA using Power Doppler ultrasound. Methods: The randomized, placebo-controlled, Phase III ULTIMATE study enrolled PsA patients with active ultrasound synovitis and clinical synovitis and enthesitis having an inadequate response to conventional DMARDs and naïve to biologic DMARDs. Patients were randomly assigned to receive either weekly subcutaneous secukinumab (300 or 150 mg according to the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The primary outcome was the mean change in the ultrasound Global EULAR and OMERACT Synovitis Score (GLOESS) from baseline to week 12. Key secondary endpoints included ACR 20 and 50 responses. Results: Of the 166 patients enrolled, 97% completed 12 weeks of treatment (secukinumab, 99%; placebo, 95%). The primary end point was met, and the adjusted mean change in GLOESS was higher with secukinumab than placebo [-9 (0.9) vs -6 (0.9), difference (95% CI): -3 (-6, -1); one-sided P=0.004] at week 12. The difference in GLOESS between secukinumab and placebo was significant as early as one week after initiation of treatment. All key secondary endpoints were met. No new or unexpected safety findings were reported. Conclusion: This unique ultrasound study shows that apart from improving the signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid and significant reduction of synovitis in PsA patients
Files in this item
Google Scholar:D'Agostino, Maria Antonietta
-
Schett, Georg
-
López Rodriguez, Alejandra
-
Šenolt, Ladislav
-
Fazekas, Katalin
-
Burgos-Vargas, Ruben
-
Maldonado-Cocco, Jose
-
Naredo Sánchez, Esperanza
-
Carron, Philippe
-
Duggan, Anne Marie
-
Goyanka, Punit
-
Boers, Maarten
-
Gaillez, Corine
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): Study protocol for a randomized controlled trial
Cabrera-García, Lourdes; Cruz-Melguizo, Sara; Ruiz-Antorán, Belén; Torres, Ferrán; Velasco, Ana; Martínez-Payo, Cristina; Avendaño Solá, Cristina; Cruz Melguizo, Sara; Cordero, Estefanía; Adiego Burgos, Begoña; Martínez Guisasola, Javier; Martínez Cortés, Luis; García González, Celso; Quesada Segura, Gonzalo; Abarca, Leopoldo; Savirón, Ricardo; Pérez Carbajo, Esther; Rodríguez León, José Alberto; Bartha Rasero, José Luis; Teulón, María; Nogales, Rosa; Rodríguez; Alonso, Gregoria; Álvbarez Colomo, Cristina; Anaya Baz, Mángeles; Abeshera Davó, Daniel; Cancelo, Maria Jesús; Díaz dee Teran, Elisa Maria; Mateu Pruñunosa, Joan Carles; Gálvez, Gloria; Torre, Antoniodela; Marqueta Sánchez, José Manuel; Bermejo, Rosa; Lekuona Artola, Arantza; Cabrillo Rodríguez, Eduardo; Dios, Emilia de
2015-09-25